Markers of endothelial dysfunction and insulin resistance. beneficial effects of rosiglitazone in type 2 diabetes

被引：0
|
作者：
Albertini, JP
Chen, HZ
Mather, R
Valensi, P
机构：
来源：
DIABETES | 2004年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A117 / A117
页数：1
相关论文
共 50 条
  • [41] Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes
    Rask-Madsen, Christian
    King, George L.
    NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (01): : 46 - 56
  • [42] Mechanisms of Disease: endothelial dysfunction in insulin resistance and diabetes
    Christian Rask-Madsen
    George L King
    Nature Clinical Practice Endocrinology & Metabolism, 2007, 3 : 46 - 56
  • [43] Cytochrome P450 induction improves endothelial dysfunction in insulin resistance.
    Katakam, PVG
    Ujhelyi, MR
    Hsu, T
    Miller, AW
    FASEB JOURNAL, 1999, 13 (05): : A834 - A834
  • [44] Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes
    Bailey, CJ
    Day, C
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2004, 58 (09) : 867 - 876
  • [45] Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes
    Stage, Tore Bjerregaard
    Christensen, Mette-Marie Hougaard
    Jorgensen, Niklas Rye
    Beck-Nielsen, Henning
    Brosen, Kim
    Gram, Jeppe
    Frost, Morten
    BONE, 2018, 112 : 35 - 41
  • [46] P.050 The Insulin Sensitizer Rosiglitazone Improves Endothelial Function in Patients with Type 2 Diabetes on Insulin
    K. Papathanassiou
    K. K. Naka
    N. Kazakos
    K. Pappas
    K. Liveris
    D. Makriyiannis
    A. Tsatsoulis
    L. K. Michalis
    Artery Research, 2006, 1 (Suppl 1) : S39 - S39
  • [47] Endothelial dysfunction, insulin resistance and non-insulin-dependent diabetes
    Chowienczyk, PJ
    Watts, GF
    ENDOCRINOLOGY AND METABOLISM, 1997, 4 (04): : 225 - 232
  • [48] The role of lipin in diabetes and insulin resistance.
    Phan, J
    Reue, K
    JOURNAL OF INVESTIGATIVE MEDICINE, 2004, 52 (01) : S152 - S152
  • [49] Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus
    Kadoglou, N. P. E.
    Iliadis, F.
    Angelopoulou, N.
    Perrea, D.
    Liapis, C. D.
    Alevizos, M.
    DIABETIC MEDICINE, 2008, 25 (03) : 333 - 340
  • [50] Endothelial dysfunction markers as a therapeutic target for Sildenafil treatment and effects on metabolic control in type 2 diabetes
    Mandosi, Elisabetta
    Giannetta, Elisa
    Filardi, Tiziana
    Lococo, Manuela
    Bertolini, Camilla
    Fallarino, Mara
    Gianfrilli, Daniele
    Venneri, Mary Anna
    Lenti, Luisa
    Lenzi, Andrea
    Morano, Susanna
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2015, 19 (12) : 1617 - 1622
12345